%0 Journal Article
%A Franco, Fernando
%A Carcereny, Enric
%A Guirado, Maria
%A Ortega, Ana L.
%A Lopez-Castro, Rafael
%A Rodriguez-Abreu, Delvys
%A Garcia-Campelo, Rosario
%A Del Barco, Edel
%A Juan, Oscar
%A Aparisi, Francisco
%A Gonzalez-Larriba, Jose L.
%A Domine, Manuel
%A Trigo, Jose M.
%A Cobo, Manuel
%A Cerezo, Sara
%A Calzas, Julia
%A Massuti, Bartomeu
%A Bosch-Barrera, Joaquim
%A Garcia Coves, Paola
%A Domenech, Marta
%A Provencio, Mariano
%T Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
%D 2021
%U http://hdl.handle.net/10668/4053
%X Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce. Patients and methods This was an observational multicenter study that enrolled patients with lung cancer and tho racic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demo graphic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed. Results With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or  2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty per cent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overallsurvival was 9.5 months (95% CI 8.8–10.2 months), with an estimated rate of 70.3% (95% CI 67.2–73.4%), 38.9% (95% CI 35.4–42.4%), and 14.8% (95% CI 11.8–17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mor tality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1–2. Long-term survival (> 2 years) was confirmed in 6.6% of patients,showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis. Conclusion This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients.
%K Epidemiology
%K Treatment
%K Survival
%K Small cell lung cancer
%K Spain
%K Thoracic tumor
%K Epidemiología
%K Terapéutica
%K Supervivencia (salud pública)
%K Carcinoma pulmonar de células pequeñas
%K España
%K Neoplasias torácicas
%~